Universität zu Köln

Journal Article

Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Shipp, Margaret A., Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto ORCID: 0000-0001-8275-2561 and Ansell, Stephen M. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J. Clin. Oncol., 36 (14). S. 1428 - 1450. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Armand, Philippe, Engert, Andreas, Younes, Anas, Lee, Hun Ju, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Savage, Kerry J., Kuruvilla, John, Trneny, Marek, Shipp, Margaret A., Sacchi, Mariana, Ansell, Anne Sumbuland Stephen M. and Ansell, Stephen M. (2018). Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Chen, Robert, Zinzani, Pier Luigi, Fanale, Michelle A., Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Zhang, Yinghua, Ricart, Alejandro D., Balakumaran, Arun and Moskowitz, Craig H. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J. Clin. Oncol., 35 (19). S. 2125 - 2135. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H. (2019). Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 134 (14). S. 1144 - 1154. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cohen, Jonathon B., Kuruvilla, John, Engert, Andreas, Ansell, Stephen M., Younes, Anas, Lee, Hun Ju, Trneny, Marek, Savage, Kerry J., Ramchandren, Radhakrishnan, Collins, Graham P., Zinzani, Pier Luigi, De Boer, Jan Paul, Shipp, Margaret A., Santoro, Armando, Timmerman, John M., Sacchi, Mariana, Sy, Oumar and Armand, Philippe (2018). Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Moskowitz, Craig H., Zinzani, Pier Luigi, Fanale, Michelle A., Armand, Philippe, Johnson, Nathalie A., Radford, John A., Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Gustafson, Eric, Zhang, Yinghua, Ricart, Alejandro Daniel, Balakumaran, Arun and Chen, Robert W. (2016). Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Roemer, Margaretha G. M., Ligon, Azra H., Engert, Andreas, Younes, Anas, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle A., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham P., Savage, Kerry J., Trneny, Marek, Neuberg, Donna S., Redd, Robert A., Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Kato, Kazunobu, Sumbul, Anne, Rodig, Scott J. and Shipp, Margaret A. (2016). Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Roemer, Margaretha G. M., Redd, Robert A., Cader, Fathima Zumla, Pak, Christine J., Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John, Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Ansell, Stephen, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S., Pinkus, Geraldine S., Ligon, Azra H., Rodig, Scott J. and Shipp, Margaret A. (2018). Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J. Clin. Oncol., 36 (10). S. 942 - 954. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Timmerman, John M., Engert, Andreas, Younes, Anas, Santoro, Armando, Armand, Philippe, Fanale, Michelle A., Collins, Graham P., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Savage, Kerry J., Trneny, Marek, De Boer, Jan Paul, Shipp, Margaret A., Rodig, Scott J., Kato, Kazunobu, Sumbul, Anne and Ansell, Stephen (2016). Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Zinzani, Pier Luigi, Chen, Robert, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John ORCID: 0000-0001-7898-2786, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H. (2020). Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk. Lymphoma, 61 (4). S. 950 - 955. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403